Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + FLOT in resectable gastric/GEJ cancer
NCT04592913Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 20
01
Overview
A Phase 3 trial of durvalumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Nov 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04592913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592913.